Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 4

Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat® Soft Mist Inhaler

Authors Richard Hodder, David Price

Published 14 October 2009 Volume 2009:4 Pages 381—390

DOI https://doi.org/10.2147/COPD.S3391

Review by Single-blind

Peer reviewer comments 2

Richard Hodder,1 David Price2

1Divisions of Pulmonary and Critical Care, University of Ottawa, Ottawa, Ontario, Canada; 2Department of General Practice and Primary Care, University of Aberdeen, Aberdeen, Scotland

Abstract: Current guidelines for the management of chronic obstructive pulmonary disease (COPD) recommend the regular use of inhaled bronchodilator therapy in order to relieve symptoms and prevent exacerbations. A variety of inhaler devices are currently available to COPD patients, and the choice of device is an important consideration because it can influence patients’ adherence to treatment, and thus potentially affect the long-term outcome. The Respimat® Soft Mist Inhaler (SMI) generates a slow-moving aerosol with a high fine particle fraction, resulting in deposition of a higher proportion of the dose in the lungs than pressurized metered-dose inhalers (pMDIs) or some dry powder inhalers (DPIs). We review clinical studies of inhaler satisfaction and preference comparing Respimat® SMI against other inhalers in COPD patients. Using objective and validated patient satisfaction instruments, Respimat® SMI was consistently shown to be well accepted by COPD patients, largely due to its inhalation and handling characteristics. In comparative studies with pMDIs, the patient total satisfaction score with Respimat® SMI was statistically and clinically significantly higher than with the pMDI. In comparative studies with DPIs, the total satisfaction score was statistically significantly higher than for the Turbuhaler® DPI, but only the performance domain of satisfaction was clinically significantly higher for Respimat® SMI. Whether the observed higher levels of patient satisfaction reported with Respimat® SMI might be expected to result in improved adherence to therapy and thus provide benefits consistent with those recently shown to be associated with sustained bronchodilator treatment in patients with COPD remains to be proven.

Keywords: Respimat® Soft Mist Inhaler, pressurized metered-dose inhalers, pressurized metered-dose inhalers, inhaler devices

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Asthma patients prefer Respimat® Soft Mist™ Inhaler to Turbuhaler®

Rick Hodder, Pat Ray Reese, Terra Slaton

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:225-232

Published Date: 26 May 2009

Readers of this article also read:

Fiber-optic triggered release of liposome in vivo: implication of personalized chemotherapy

Huang HL, Lu PH, Yang HC, Lee GD, Li HR, Liao KC

International Journal of Nanomedicine 2015, 10:5171-5185

Published Date: 14 August 2015

Comparison of two self-assembled macromolecular prodrug micelles with different conjugate positions of SN38 for enhancing antitumor activity

Liu Y, Piao HY, Gao Y, Xu CH, Tian Y, Wang LH, Liu JW, Tang B, Zou MJ, Cheng G

International Journal of Nanomedicine 2015, 10:2295-2311

Published Date: 23 March 2015

Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations

Pomares X, Montón C, Espasa M, Casabon J, Monsó E, Gallego M

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:449-456

Published Date: 6 September 2011

Prevalence and risk factors for unrecognized obstructive lung disease among urban drug users

M Bradley Drummond, Gregory D Kirk, Jacquie Astemborski, et al

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:89-95

Published Date: 19 January 2011

Noninvasive ventilation: has Pandora’s box been opened?

Ari Manuel, Richard EK Russell, Quentin Jones

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:55-56

Published Date: 24 February 2010

Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study

Niels H Chavannes, Tjard RJ Schermer, Emiel FM Wouters, et al

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:431-436

Published Date: 19 November 2009

Long-term therapy in COPD: any evidence of adverse effect on bone?

Arnulf Langhammer, Siri Forsmo, Unni Syversen

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:365-380

Published Date: 30 September 2009

Beta-blockers and health-related quality of life in patients with peripheral arterial disease and COPD

Yvette RBM van Gestel, Sanne E Hoeks, Don D Sin, Henk Stam, Frans W Mertens, Jeroen J Bax, Ron T van Domburg, Don Poldermans

International Journal of Chronic Obstructive Pulmonary Disease 2009, 4:177-183

Published Date: 8 May 2009